通讯作者: 尹文强, yinwq1969@126.com

DOI：10.12201/bmr.202203.00006

Study on Chinas centralized quantity purchasing policy for drugs from the perspective of stakeholders - a textual analysis based on policy tools

• 摘要：目的：通过对我国药品集中带量采购相关政策文本进行剖析，探讨现有政策侧重点及不足，以期为我国未来药品集中带量采购政策制定及优化提供参考依据。方法：采用内容分析法，选取16份药品集中带量采购相关政策为研究对象，基于政策工具及利益相关者两个维度进行分析。结果：政策工具维度共筛选出147个政策编码，其中命令与规制型工具占56.5%（83/147）、激励型工具占3.4%（5/147）、能力建设型工具占28.6%（42/147）、系统变革型工具占2.0%（3/147）、信息与劝诫型工具占9.5%（14/147）；利益相关者维度共筛选出323个政策编码，其中药品生产企业占20.7%（67/323）、药品流通企业占6.8%（22/323）、政府相关部门占34.1%（110/323）、医疗机构占29.1%（94/323）、患者占9.3%（30/323）。结论：分析发现政策工具结构不均衡，利益相关者格局不协调，政策工具与利益相关者耦合性不强，应结合药品集中带量采购政策特征及发展趋势优化各类政策工具使用比例；兼顾多方利益相关者，增强利益相关者凝聚力；推进政策工具与利益相关者有效结合，提高政策的靶向精准度。

  关键词： 药品集中带量采购；政策工具；利益相关者；政策分析; ; ; 

   

  Abstract: Objective: By analyzing the relevant policy texts of Chinas Centralized volume-based drug purchase, this paper discusses the key points and shortcomings of the existing policy tools, to provide a reference basis for the formulation and optimization of Chinas centralized drug procurement policy in the future. Methods: Using the content analysis method, 16 policies related to centralized quantity procurement of drugs were selected for the study and analyzed based on two dimensions of policy tools and stakeholders. Results: A total of 147 policy codes were selected from the dimension of policy tools, among which command and regulation tools accounted for 56.5% (83/147), incentive tools accounted for 3.4% (5/147), capacity-building tools accounted for 28.6% (42/147), system transformation tools accounted for 2.0% (3/147), information and persuasion tools accounted for 9.5% (14/147); A total of 323 policy codes were screened out from the stakeholder dimension, including 20.7% (67/323) drug manufacturers, 6.8% (22/323) drug distribution enterprises, 34.1% (110/323) government departments, 29.1% (94/323) medical institutions, and 9.3% (30/323) patients. Conclusion: The analysis found that the structure of policy tools is unbalanced, the pattern of stakeholders is not coordinated, and the coupling between policy tools and stakeholders is not strong. The use ratio of various policy tools should be optimized by taking into account the characteristics and development trend of centralized volume-based drug procurement policy; taking into account multiple stakeholders and enhancing the cohesiveness of stakeholders; promoting the effective combination of policy tools and stakeholders and improving the targeting accuracy of policies.

  Key words: Centralized volume-based drug purchase; Policy tools; Stakeholder; Policy analysis

  提交时间：2022-03-21

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 荣红国, 邢叶一祎, 董玥, 夏如玉, 商洪才, 刘建平, 费宇彤. 政策工具视角下我国抗菌药物合理用药政策研究. 2021. doi: 10.12201/bmr.202107.00021

  孙言, 朱正, 杨莉. 国家组织药品集中带量采购价格降幅影响因素分析. 2022. doi: 10.12201/bmr.202203.00008

  李新宇, 邵蓉, 白铭钰, 李大双, 颜建周. 我国儿童药保障政策文本量化分析——基于政策工具、政策目标的二维框架. 2022. doi: 10.12201/bmr.202209.00016

  蒋明珠, 应晓华. 我国疫苗管理政策文本的量化研究 -基于政策工具、政策主体、政策落点的文本分析. 2022. doi: 10.12201/bmr.202212.00005

  周立芳, 吕海源, 邵佳娴, 尹文强, 于云聪, 马东平, 陈钟鸣. 新医改以来我国乡村医生相关政策量化研究: 基于政策工具、靶点和力度. 2022. doi: 10.12201/bmr.202203.00011

  黄石松, 孙书彦. 政策工具视角下我国养老服务体系建设研究. 2022. doi: 10.12201/bmr.202210.00018

  曾叙衡, 郑颐, 吕军, 宁玉玲, 励晓红. 实施高值医用耗材带量采购的SWOT分析——以上海市为例. 2020. doi: 10.12201/bmr.202010.00841

  马文雯, 李超凡, 刘聪慧, 孙强. 我国医防协同政策文本量化分析——基于政策工具、协同层次和协同机制的三维框架. 2022. doi: 10.12201/bmr.202209.00007

  龚浩, 周罗晶. 基于数字挖掘的我国互联网医疗政策文本分析. 2022. doi: 10.12201/bmr.202208.00005

  李洪宇, 孙强. “两票制”政策对山东省药品供应状况影响分析. 2021. doi: 10.12201/bmr.202011.00015

• 序号	提交日期	编号	操作
  1	2021-12-21	bmr.202203.00006V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论